Polyomavirus infections occur commonly in humans and are normally nonfatal. However, in immunocompromised individuals, they are intractable and frequently fatal. Due to a lack of approved drugs to treat polyomavirus infections, cidofovir, a phosphonate nucleotide analog approved to treat cytomegalovirus infections, has been repurposed as an antipolyomavirus agent. Cidofovir has been modified in various ways to improve its efficacies as a broad-spectrum antiviral agent. However, the actual mechanisms and targets of cidofovir and its modified derivatives as antipolyomavirus agents are still under research. Here, polyomavirus large tumor antigen (Tag) activities were identified as the viral target of cidofovir derivatives. The alkoxyalkyl ester derivatives of cidofovir efficiently inhibit polyomavirus DNA replication in cell-free human extracts and a viral in vitro replication system utilizing only purified proteins. We present evidence that DNA helicase and DNA binding activities of polyomavirus Tags are diminished in the presence of low concentrations of alkoxyalkyl ester derivatives of cidofovir, suggesting that the inhibition of viral DNA replication is at least in part mediated by inhibiting single-stranded DNA (ssDNA) and double-stranded DNA (dsDNA) binding activities of Tags. These findings show that the alkoxyalkyl ester derivatives of cidofovir are effective in vitro without undergoing further conversions, and we conclude that the inhibitory mechanisms of nucleotide analog-based drugs are more complex than previously believed.

Biochemistry School of Natural Science and Centre for Chromosome Biology NUI Galway Galway Ireland

Institute of Organic Chemistry and Biochemistry Czech Academy of Sciences Prague Czech Republic

Zobrazit více v PubMed

Delbue S, Comar M, Ferrante P. 2017. Review on the role of the human Polyomavirus JC in the development of tumors. Infect Agents Cancer 12:10. doi:10.1186/s13027-017-0122-0. PubMed DOI PMC

Payne S. 2017. Family Polyomaviridae, p 247–251. In Payne S (ed), Viruses from understanding to investigation. doi:10.1016/B978-0-12-803109-4.00031-3. Academic Press, San Diego, CA. DOI

van der Meijden E, Horváth B, Nijland M, de Vries K, Rácz EK, Diercks GF, de Weerd AE, Clahsen-van Groningen MC, van der Blij-de Brouwer CS, van der Zon AJ, Kroes ACM, Hedman K, van Kampen JJA, Riezebos-Brilman A, Feltkamp MCW. 2017. Primary polyomavirus infection, not reactivation, as the cause of trichodysplasia spinulosa in immunocompromised patients. J Infect Dis 215:1080–1084. doi:10.1093/infdis/jiw403. PubMed DOI

White MK, Gordon J, Khalili K. 2013. The rapidly expanding family of human polyomaviruses: recent developments in understanding their life cycle and role in human pathology. PLoS Pathog 9:e1003206. doi:10.1371/journal.ppat.1003206. PubMed DOI PMC

Ambalathingal GR, Francis RS, Smyth MJ, Smith C, Khanna R. 2017. BK polyomavirus: clinical aspects, immune regulation, and emerging therapies. Clin Microbiol Rev 30:503–528. doi:10.1128/CMR.00074-16. PubMed DOI PMC

Atkinson AL, Atwood WJ. 2020. Fifty years of JC polyomavirus: a brief overview and remaining questions. Viruses 12:969. doi:10.3390/v12090969. PubMed DOI PMC

Dalianis T, Eriksson BM, Felldin M, Friman V, Hammarin AL, Herthelius M, Ljungman P, Mölne J, Wennberg L, Swartling L. 2019. Management of BK-virus infection: Swedish recommendations. Infect Dis (Lond) 51:479–484. doi:10.1080/23744235.2019.1595130. PubMed DOI

Satyanarayana G, Marty FM, Tan CS. 2014. The polyomavirus puzzle: is host immune response beneficial in controlling BK virus after adult hematopoietic cell transplantion? Transpl Infect Dis 16:521–531. doi:10.1111/tid.12233. PubMed DOI PMC

Ho HT, Woods KL, Bronson JJ, De Boeck H, Martin JC, Hitchcock MJ. 1992. Intracellular metabolism of the antiherpes agent (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine. Mol Pharmacol 41:197–202. PubMed

Kuypers DR, Vandooren AK, Lerut E, Evenepoel P, Claes K, Snoeck R, Naesens L, Vanrenterghem Y. 2005. Adjuvant low-dose cidofovir therapy for BK polyomavirus interstitial nephritis in renal transplant recipients. Am J Transplant 5:1997–2004. doi:10.1111/j.1600-6143.2005.00980.x. PubMed DOI

Lalezari JP, Holland GN, Kramer F, McKinley GF, Kemper CA, Ives DV, Nelson R, Hardy WD, Kuppermann BD, Northfelt DW, Youle M, Johnson M, Lewis RA, Weinberg DV, Simon GL, Wolitz RA, Ruby AE, Stagg RJ, Jaffe HS. 1998. Randomized, controlled study of the safety and efficacy of intravenous cidofovir for the treatment of relapsing cytomegalovirus retinitis in patients with AIDS. J Acquir Immune Defic Syndr Hum Retrovirol 17:339–344. doi:10.1097/00042560-199804010-00008. PubMed DOI

Magee WC, Aldern KA, Hostetler KY, Evans DH. 2008. Cidofovir and (S)-9-[3-hydroxy-(2-phosphonomethoxy)propyl]adenine are highly effective inhibitors of vaccinia virus DNA polymerase when incorporated into the template strand. Antimicrob Agents Chemother 52:586–597. doi:10.1128/AAC.01172-07. PubMed DOI PMC

Magee WC, Hostetler KY, Evans DH. 2005. Mechanism of inhibition of vaccinia virus DNA polymerase by cidofovir diphosphate. Antimicrob Agents Chemother 49:3153–3162. doi:10.1128/AAC.49.8.3153-3162.2005. PubMed DOI PMC

Topalis D, Lebeau I, Krecmerová M, Andrei G, Snoeck R. 2011. Activities of different classes of acyclic nucleoside phosphonates against BK virus in primary human renal cells. Antimicrob Agents Chemother 55:1961–1967. doi:10.1128/AAC.01809-10. PubMed DOI PMC

Cundy KC. 1999. Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir. Clin Pharmacokinet 36:127–143. doi:10.2165/00003088-199936020-00004. PubMed DOI

Cundy KC, Bidgood AM, Lynch G, Shaw JP, Griffin L, Lee WA. 1996. Pharmacokinetics, bioavailability, metabolism, and tissue distribution of cidofovir (HPMPC) and cyclic HPMPC in rats. Drug Metab Dispos 24:745–752. PubMed

Xiong X, Smith JL, Chen MS. 1997. Effect of incorporation of cidofovir into DNA by human cytomegalovirus DNA polymerase on DNA elongation. Antimicrob Agents Chemother 41:594–599. doi:10.1128/AAC.41.3.594. PubMed DOI PMC

Xiong X, Smith JL, Kim C, Huang ES, Chen MS. 1996. Kinetic analysis of the interaction of cidofovir diphosphate with human cytomegalovirus DNA polymerase. Biochem Pharmacol 51:1563–1567. doi:10.1016/0006-2952(96)00100-1. PubMed DOI

Bullock PA. 1997. The initiation of simian virus 40 DNA replication in vitro. Crit Rev Biochem Mol Biol 32:503–568. doi:10.3109/10409239709082001. PubMed DOI

Stenlund A. 2003. Initiation of DNA replication: lessons from viral initiator proteins. Nat Rev Mol Cell Biol 4:777–785. doi:10.1038/nrm1226. PubMed DOI

Waga S, Stillman B. 1994. Anatomy of a DNA replication fork revealed by reconstitution of SV40 DNA replication in vitro. Nature 369:207–212. doi:10.1038/369207a0. PubMed DOI

Beadle JR. 2007. Synthesis of cidofovir and (S)-HPMPA ether lipid prodrugs. Curr Protoc Nucleic Acids Chem Chapter 15:Unit 15.12. doi:10.1002/0471142700.nc1502s29. PubMed DOI

Beadle JR, Hartline C, Aldern KA, Rodriguez N, Harden E, Kern ER, Hostetler KY. 2002. Alkoxyalkyl esters of cidofovir and cyclic cidofovir exhibit multiple-log enhancement of antiviral activity against cytomegalovirus and herpesvirus replication in vitro. Antimicrob Agents Chemother 46:2381–2386. doi:10.1128/aac.46.8.2381-2386.2002. PubMed DOI PMC

Ciesla SL, Trahan J, Wan WB, Beadle JR, Aldern KA, Painter GR, Hostetler KY. 2003. Esterification of cidofovir with alkoxyalkanols increases oral bioavailability and diminishes drug accumulation in kidney. Antiviral Res 59:163–171. doi:10.1016/s0166-3542(03)00110-4. PubMed DOI

Krecmerová M, Holý A, Pískala A, Masojídková M, Andrei G, Naesens L, Neyts J, Balzarini J, De Clercq E, Snoeck R. 2007. Antiviral activity of triazine analogues of 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine (cidofovir) and related compounds. J Med Chem 50:1069–1077. doi:10.1021/jm061281. PubMed DOI

Krecmerová M, Holý A, Pohl R, Masojídková M, Andrei G, Naesens L, Neyts J, Balzarini J, De Clercq E, Snoeck R. 2007. Ester prodrugs of cyclic 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine: synthesis and antiviral activity. J Med Chem 50:5765–5772. doi:10.1021/jm0707166. PubMed DOI

Krecmerová M, Masojídková M, Holý A. 2010. Acyclic nucleoside phosphonates with 5-azacytosine base moiety substituted in C-6 position. Bioorg Med Chem 18:387–395. doi:10.1016/j.bmc.2009.10.044. PubMed DOI

Smee DF, Wong MH, Bailey KW, Beadle JR, Hostetler KY, Sidwell RW. 2004. Effects of four antiviral substances on lethal vaccinia virus (IHD strain) respiratory infections in mice. Int J Antimicrob Agents 23:430–437. doi:10.1016/j.ijantimicag.2003.10.010. PubMed DOI

Hostetler KY. 2009. Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral activity and reduce toxicity: current state of the art. Antiviral Res 82:A84–98. doi:10.1016/j.antiviral.2009.01.005. PubMed DOI PMC

Parker S, Touchette E, Oberle C, Almond M, Robertson A, Trost LC, Lampert B, Painter G, Buller RM. 2008. Efficacy of therapeutic intervention with an oral ether-lipid analogue of cidofovir (CMX001) in a lethal mousepox model. Antiviral Res 77:39–49. doi:10.1016/j.antiviral.2007.08.003. PubMed DOI PMC

Quenelle DC, Prichard MN, Keith KA, Hruby DE, Jordan R, Painter GR, Robertson A, Kern ER. 2007. Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses. Antimicrob Agents Chemother 51:4118–4124. doi:10.1128/AAC.00762-07. PubMed DOI PMC

Wan WB, Beadle JR, Hartline C, Kern ER, Ciesla SL, Valiaeva N, Hostetler KY. 2005. Comparison of the antiviral activities of alkoxyalkyl and alkyl esters of cidofovir against human and murine cytomegalovirus replication in vitro. Antimicrob Agents Chemother 49:656–662. doi:10.1128/AAC.49.2.656-662.2005. PubMed DOI PMC

Araya CE, Lew JF, Fennell RS, 3rd, Neiberger RE, Dharnidharka VR. 2006. Intermediate-dose cidofovir without probenecid in the treatment of BK virus allograft nephropathy. Pediatr Transplant 10:32–37. doi:10.1111/j.1399-3046.2005.00391.x. PubMed DOI

Araya CE, Lew JF, Fennell RS, Neiberger RE, Dharnidharka VR. 2008. Intermediate dose cidofovir does not cause additive nephrotoxicity in BK virus allograft nephropathy. Pediatr Transplant 12:790–795. doi:10.1111/j.1399-3046.2008.00937.x. PubMed DOI

Elfadawy N, Yamada M, Sarabu N. 2018. Management of BK polyomavirus infection in kidney and kidney-pancreas transplant recipients: a review article. Infect Dis Clin North Am 32:599–613. doi:10.1016/j.idc.2018.04.009. PubMed DOI

Garces JC. 2010. BK virus-associated nephropathy in kidney transplant recipients. Ochsner J 10:245–249. PubMed PMC

Hostetler KY. 2010. Synthesis and early development of hexadecyloxypropylcidofovir: an oral antipoxvirus nucleoside phosphonate. Viruses 2:2213–2225. doi:10.3390/v2102213. PubMed DOI PMC

Trofe J, Gaber LW, Stratta RJ, Shokouh-Amiri MH, Vera SR, Alloway RR, Lo A, Gaber AO, Egidi MF. 2003. Polyomavirus in kidney and kidney-pancreas transplant recipients. Transpl Infect Dis 5:21–28. doi:10.1034/j.1399-3062.2003.00009.x. PubMed DOI

Wadei HM, Rule AD, Lewin M, Mahale AS, Khamash HA, Schwab TR, Gloor JM, Textor SC, Fidler ME, Lager DJ, Larson TS, Stegall MD, Cosio FG, Griffin MD. 2006. Kidney transplant function and histological clearance of virus following diagnosis of polyomavirus-associated nephropathy (PVAN). Am J Transplant 6:1025–1032. doi:10.1111/j.1600-6143.2006.01296.x. PubMed DOI

Bernhoff E, Gutteberg TJ, Sandvik K, Hirsch HH, Rinaldo CH. 2008. Cidofovir inhibits polyomavirus BK replication in human renal tubular cells downstream of viral early gene expression. Am J Transplant 8:1413–1422. doi:10.1111/j.1600-6143.2008.02269.x. PubMed DOI

Farasati NA, Shapiro R, Vats A, Randhawa P. 2005. Effect of leflunomide and cidofovir on replication of BK virus in an in vitro culture system. Transplantation 79:116–118. doi:10.1097/01.tp.0000149338.97084.5f. PubMed DOI

Kadambi PV, Josephson MA, Williams J, Corey L, Jerome KR, Meehan SM, Limaye AP. 2003. Treatment of refractory BK virus-associated nephropathy with cidofovir. Am J Transplant 3:186–191. doi:10.1034/j.1600-6143.2003.30202.x. PubMed DOI

Lim WH, Mathew TH, Cooper JE, Bowden S, Russ GR. 2003. Use of cidofovir in polyomavirus BK viral nephropathy in two renal allograft recipients. Nephrology (Carlton) 8:318–323. doi:10.1111/j.1440-1797.2008.00214.x. PubMed DOI

Lipshutz GS, Mahanty H, Feng S, Hirose R, Stock PG, Kang SM, Posselt AM, Freise CE. 2005. BKV in simultaneous pancreas-kidney transplant recipients: a leading cause of renal graft loss in first 2 years post-transplant. Am J Transplant 5:366–373. doi:10.1111/j.1600-6143.2004.00685.x. PubMed DOI

Ramos E, Drachenberg CB, Wali R, Hirsch HH. 2009. The decade of polyomavirus BK-associated nephropathy: state of affairs. Transplantation 87:621–630. doi:10.1097/TP.0b013e318197c17d. PubMed DOI

Vats A, Shapiro R, Singh Randhawa P, Scantlebury V, Tuzuner A, Saxena M, Moritz ML, Beattie TJ, Gonwa T, Green MD, Ellis D. 2003. Quantitative viral load monitoring and cidofovir therapy for the management of BK virus-associated nephropathy in children and adults. Transplantation 75:105–112. doi:10.1097/00007890-200301150-00020. PubMed DOI

Bidanset DJ, Beadle JR, Wan WB, Hostetler KY, Kern ER. 2004. Oral activity of ether lipid ester prodrugs of cidofovir against experimental human cytomegalovirus infection. J Infect Dis 190:499–503. doi:10.1086/421912. PubMed DOI

Williams-Aziz SL, Hartline CB, Harden EA, Daily SL, Prichard MN, Kushner NL, Beadle JR, Wan WB, Hostetler KY, Kern ER. 2005. Comparative activities of lipid esters of cidofovir and cyclic cidofovir against replication of herpesviruses in vitro. Antimicrob Agents Chemother 49:3724–3733. doi:10.1128/AAC.49.9.3724-3733.2005. PubMed DOI PMC

Seguin SP, Ireland AW, Gupta T, Wright CM, Miyata Y, Wipf P, Pipas JM, Gestwicki JE, Brodsky JL. 2012. A screen for modulators of large T antigen’s ATPase activity uncovers novel inhibitors of simian virus 40 and BK virus replication. Antiviral Res 96:70–81. doi:10.1016/j.antiviral.2012.07.012. PubMed DOI PMC

Wright CM, Seguin SP, Fewell SW, Zhang H, Ishwad C, Vats A, Lingwood CA, Wipf P, Fanning E, Pipas JM, Brodsky JL. 2009. Inhibition of simian virus 40 replication by targeting the molecular chaperone function and ATPase activity of T antigen. Virus Res 141:71–80. doi:10.1016/j.virusres.2008.12.018. PubMed DOI PMC

Onwubiko NO, Borst A, Diaz SA, Passkowski K, Scheffel F, Tessmer I, Nasheuer HP. 2020. SV40 T antigen interactions with ssDNA and replication protein A: a regulatory role of T antigen monomers in lagging strand DNA replication. Nucleic Acids Res 48:3657–3677. doi:10.1093/nar/gkaa138. PubMed DOI PMC

Fanning E, Knippers R. 1992. Structure and function of simian virus 40 large tumor antigen. Annu Rev Biochem 61:55–85. doi:10.1146/annurev.bi.61.070192.000415. PubMed DOI

De Clercq E. 2007. The acyclic nucleoside phosphonates from inception to clinical use: historical perspective. Antiviral Res 75:1–13. doi:10.1016/j.antiviral.2006.10.006. PubMed DOI

De Clercq E. 2012. Milestones in the discovery of antiviral agents: nucleosides and nucleotides. Acta Pharmaceutica Sinica B 2:535–548. doi:10.1016/j.apsb.2012.10.001. DOI

De Clercq E, Holý A, Rosenberg I, Sakuma T, Balzarini J, Maudgal PC. 1986. A novel selective broad-spectrum anti-DNA virus agent. Nature 323:464–467. doi:10.1038/323464a0. PubMed DOI

Hoh HB, Hurley C, Claoue C, Viswalingham M, Easty DL, Goldschmidt P, Collum LM. 1996. Randomised trial of ganciclovir and acyclovir in the treatment of herpes simplex dendritic keratitis: a multicentre study. Br J Ophthalmol 80:140–143. doi:10.1136/bjo.80.2.140. PubMed DOI PMC

Wagstaff AJ, Faulds D, Goa KL. 1994. Aciclovir: a reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. Drugs 47:153–205. doi:10.2165/00003495-199447010-00009. PubMed DOI

Krečmerová M, Masojídková M, Holý A. 2006. Preparation of C-5 substituted cidofovir derivatives. Collect Czech Chem Commun (Camb) 71:579–594. doi:10.1135/cccc20060579. DOI

Krečmerová M, Otmar M. 2012. 5-azacytosine compounds in medicinal chemistry: current stage and future perspectives. Future Med Chem 4:991–1005. doi:10.4155/fmc.12.36. PubMed DOI

Toth K, Spencer JF, Dhar D, Sagartz JE, Buller RM, Painter GR, Wold WS. 2008. Hexadecyloxypropyl-cidofovir, CMX001, prevents adenovirus-induced mortality in a permissive, immunosuppressed animal model. Proc Natl Acad Sci U S A 105:7293–7297. doi:10.1073/pnas.0800200105. PubMed DOI PMC

Bridges B, Donegan S, Badros A. 2006. Cidofovir bladder instillation for the treatment of BK hemorrhagic cystitis after allogeneic stem cell transplantation. Am J Hematol 81:535–537. doi:10.1002/ajh.20567. PubMed DOI

Coomes EA, Wolfe Jacques A, Michelis FV, Kim DDH, Thyagu S, Viswabandya A, Lipton JH, Messner HA, Deotare U. 2018. Efficacy of cidofovir in treatment of BK virus-induced hemorrhagic cystitis in allogeneic hematopoietic cell transplant recipients. Biol Blood Marrow Transplant 24:1901–1905. doi:10.1016/j.bbmt.2018.04.009. PubMed DOI

Ganguly N, Clough LA, Dubois LK, McGuirk JP, Abhyankar S, Aljitawi OS, O'Neal N, Divine CL, Ganguly S. 2010. Low-dose cidofovir in the treatment of symptomatic BK virus infection in patients undergoing allogeneic hematopoietic stem cell transplantation: a retrospective analysis of an algorithmic approach. Transpl Infect Dis 12:406–411. doi:10.1111/j.1399-3062.2010.00513.x. PubMed DOI

Harkensee C, Vasdev N, Gennery AR, Willetts IE, Taylor C. 2008. Prevention and management of BK-virus associated haemorrhagic cystitis in children following haematopoietic stem cell transplantation–a systematic review and evidence-based guidance for clinical management. Br J Haematol 142:717–731. doi:10.1111/j.1365-2141.2008.07254.x. PubMed DOI

Philippe M, Ranchon F, Gilis L, Schwiertz V, Vantard N, Ader F, Labussiere-Wallet H, Thomas X, Nicolini FE, Wattel E, Ducastelle-Leprêtre S, Barraco F, Lebras L, Salles G, Michallet M, Rioufol C. 2016. Cidofovir in the treatment of BK virus-associated hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 22:723–730. doi:10.1016/j.bbmt.2015.12.009. PubMed DOI

An P, Sáenz Robles MT, Pipas JM. 2012. Large T antigens of polyomaviruses: amazing molecular machines. Annu Rev Microbiol 66:213–236. doi:10.1146/annurev-micro-092611-150154. PubMed DOI

Ruiz J, Beadle JR, Buller RM, Schreiwer J, Prichard MN, Keith KA, Lewis KC, Hostetler KY. 2011. Synthesis, metabolic stability and antiviral evaluation of various alkoxyalkyl esters of cidofovir and 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]adenine. Bioorg Med Chem 19:2950–2958. doi:10.1016/j.bmc.2011.03.034. PubMed DOI PMC

Ayyagari VN, Brard L. 2014. Bithionol inhibits ovarian cancer cell growth in vitro - studies on mechanism(s) of action. BMC Cancer 14:61. doi:10.1186/1471-2407-14-61. PubMed DOI PMC

Kern ER, Hartline C, Harden E, Keith K, Rodriguez N, Beadle JR, Hostetler KY. 2002. Enhanced inhibition of orthopoxvirus replication in vitro by alkoxyalkyl esters of cidofovir and cyclic cidofovir. Antimicrob Agents Chemother 46:991–995. doi:10.1128/aac.46.4.991-995.2002. PubMed DOI PMC

Stadlbauer F, Voitenleitner C, Brückner A, Fanning E, Nasheuer HP. 1996. Species-specific replication of simian virus 40 DNA in vitro requires the p180 subunit of human DNA polymerase alpha-primase. Mol Cell Biol 16:94–104. doi:10.1128/mcb.16.1.94. PubMed DOI PMC

Mahon C, Liang B, Tikhanovich I, Abend JR, Imperiale MJ, Nasheuer HP, Folk WR. 2009. Restriction of human polyomavirus BK virus DNA replication in murine cells and extracts. J Virol 83:5708–5717. doi:10.1128/JVI.00300-09. PubMed DOI PMC

Nesper J, Smith RWP, Kautz AR, Sock E, Wegner M, Grummt F, Nasheuer HP. 1997. A cell-free replication system for human polyomavirus JC DNA. J Virol 71:7421–7428. doi:10.1128/JVI.71.10.7421-7428.1997. PubMed DOI PMC

Tikhanovich I, Liang B, Seoighe C, Folk WR, Nasheuer HP. 2011. Inhibition of human BK polyomavirus replication by small noncoding RNAs. J Virol 85:6930–6940. doi:10.1128/JVI.00547-11. PubMed DOI PMC

Melle C, Nasheuer HP. 2002. Physical and functional interactions of the tumor suppressor protein p53 and DNA polymerase alpha-primase. Nucleic Acids Res 30:1493–1499. doi:10.1093/nar/30.7.1493. PubMed DOI PMC

Stadlbauer F, Brueckner A, Rehfuess C, Eckerskorn C, Lottspeich F, Förster V, Tseng BY, Nasheuer HP. 1994. DNA replication in vitro by recombinant DNA-polymerase-α-primase. Eur J Biochem 222:781–793. doi:10.1111/j.1432-1033.1994.tb18925.x. PubMed DOI

Nasheuer HP, Grosse F. 1987. Immunoaffinity-purified DNA polymerase α displays novel properties. Biochemistry 26:8458–8466. doi:10.1021/bi00399a064. PubMed DOI

Nasheuer H-P, Grosse F. 1988. DNA polymerase a-primase from calf thymus: determination of the polypeptide responsible for primase activity. J Biol Chem 263:8981–8988. PubMed

Soe K, Dianov G, Nasheuer HP, Bohr VA, Grosse F, Stevnsner T. 2001. A human topoisomerase I cleavage complex is recognized by an additional human topisomerase I molecule in vitro. Nucleic Acids Res 29:3195–3203. doi:10.1093/nar/29.15.3195. PubMed DOI PMC

Stewart L, Ireton GC, Champoux JJ. 1997. Reconstitution of human topoisomerase I by fragment complementation. J Mol Biol 269:355–372. doi:10.1006/jmbi.1997.1056. PubMed DOI

Weisshart K, Förster H, Kremmer E, Schlott B, Grosse F, Nasheuer HP. 2000. Protein-protein interactions of the primase subunits p58 and p48 with simian virus 40 T antigen are required for efficient primer synthesis in a cell-free system. J Biol Chem 275:17328–17337. doi:10.1074/jbc.M000717200. PubMed DOI

Weisshart K, Pestryakov P, Smith RW, Hartmann H, Kremmer E, Lavrik O, Nasheuer HP. 2004. Coordinated regulation of replication protein A activities by its subunits p14 and p32. J Biol Chem 279:35368–35376. doi:10.1074/jbc.M403825200. PubMed DOI

Nasheuer HP, von Winkler D, Schneider C, Dornreiter I, Gilbert I, Fanning E. 1992. Purification and functional characterization of bovine RP-A in an in vitro SV40 DNA replication system. Chromosoma 102:S52–S59. doi:10.1007/BF02451786. PubMed DOI

Scheffner M, Knippers R, Stahl H. 1989. RNA unwinding activity of SV40 large T antigen. Cell 57:955–963. doi:10.1016/0092-8674(89)90334-6. PubMed DOI